Gennady Landa, MD, is vice chair, clinical integration of ophthalmology, Mount Sinai Health System; director of retina service, NYEEI; and associate professor of ophthalmology, vitreoretinal surgeon ...
This drug is the world’s first-ever CRISPR/Cas13 RNA-editing therapy for clinical use in treating neovascular age-related macular degeneration (nAMD). The US FDA has cleared an investigational new ...
The trial evaluated nesvategrast (OTT166 5%) eye drops in patients with diabetic retinopathy. OcuTerra announced topline results from its phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) ...
Recapping a recent conversation led by Dilsher S. Dhoot, MD. In May 2025, Dilsher S. Dhoot, MD, moderated a Case-Based Roundtable® that brought together practicing retina specialists and residents ...
Manufacturers are stepping up to design products that will help maximize the safety and efficiency of intravitreal injection. The ideal syringe for administering intravitreal injections does not exist ...
The completion of the full BLA submission is anticipated in early 2026 and is eligible for priority review under the program’s fast-track designation. Today Nanoscope Therapeutics announced its ...
Eyestem received approval from India’s Central Drugs Standards Control Organisation (CDSCO) to commence human trials for Eyecyte RPE, a potential treatment for geographic atrophy arising from dry ...
Altris also has advanced AI models to enable vendor-neutral retina layers segmentation as well as detection and visualization of more than 70 retina conditions such as dry and wet age-related macular ...
These continued studies also demonstrate a well-tolerated safety profile in a broad population of more than 1,200 patients. Results from the phase 3 OAKS and DERBY studies evaluating pegcetacoplan ...
Drs Nathan Steinle, Adrienne Scott, Carl Regillo, and Prethy Rao highlight gene therapy as a future treatment of neovascular AMD and DME and how it will significantly reduce the burden on patients.
The trial is expected to close randomization in early December 2024. More than 300 patients have been randomized in the SOL-1 Phase 3 trial for OTX-TKI (AXPAXLI, axitinib intravitreal implant). The ...
Two FDA-approved geographic atrophy treatments show significant patient dropout, with 45% discontinuation by 18 months, driven by baseline vision, CNV, and lack of immediate visual improvement. In a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results